The program launches with experts from KHJ Brand Activation, Greenberg Traurig & Porzio Life Sciences discussing the challenges and opportunities facing the medical device industry in today’s market. Informative and provocative, the spark starts here.
Topic: Don’t fall off the patent cliff: Patent reform presents both challenges and opportunities for med tech companies, as new US patent law is enacted that affects patent filing and prosecution, the U.S. Patent and Trademark Office (USPTO) initiates new examination options, and the U.S. Supreme Court delivers important decisions that impact patent prosecution, litigation, and licensing strategy.
The America Invents Act (AIA) represents the first legislative change to the U.S.
Patent system in the past 60 years. Significant changes from “first to invent” to “first to file” for patents are slated to go into effect in March 2013. Med tech companies need to know how the changes will affect their ability to create and defend intellectual property.
Greenberg Traurig will chair a panel discussion that explores the legal and industry issues impacting how med tech companies can develop, manage, and assert their patent portfolios, secure funding, and achieve growth.
Panelists will provide an overview of the patent reforms initiated by Congress, the USPTO, and the Supreme Court including:
- Landmark America Invents Act that shifts U.S. patent system from a “first to invent” to a “first to file” system
- USPTO’s initiatives for accelerated patent examination processes addressing the patent application backlog
- Supreme Court’s and Federal Circuit’s issuance of far-reaching opinions, including the recent decisions in Mayo v. Prometheus Labs and Association for Molecular Pathology v. USPTO and Myriad Genetics
- Patent litigation strategies to maximize success
David Dykeman, shareholder, Greenberg Traurig, is a registered patent attorney with over fifteen years of experience in patent and intellectual property law. David’s practice focuses on securing worldwide intellectual property protection and related business strategy for high tech clients, with particular experience in medical devices, nanotechnology, information technology and life sciences.
David provides strategic patent portfolio development and intellectual property advice for clients including major research institutions, multi-national corporations, and start-up companies. He also performs patent due diligence to assess patent portfolios for venture capital investment, mergers and acquisitions, and licensing opportunities.
Topic: Embracing Compliance -Considerations for Medical Device Companies: Whether you are nearing clearance/approval, getting ready to launch a new technology or you have been marketing a product for years, compliance is an important, if not an essential, consideration for your business. In this interactive session, we will highlight hot topics in compliance that are impacting the medical device industry and discuss how you can reduce compliance risk, while still meeting your development and commercialization objectives. We will focus on those requirements (as determined by FDA, FTC, DOJ and other agencies) that relate to communication of information about your products, and that impact your relationships and interactions with healthcare professionals, and we will discuss how to “operationalize” compliance to achieve business success.
Michelle Axelrod brings over 15 years of in-house experience at leading life sciences and related healthcare organizations to her role as Principal, Porzio, Bromberg & Newman and Vice President, Porzio Life Sciences. Michelle offers valuable insights and provides innovative ideas to support business goals while effectively protecting companies and reducing organizational risk. She counsels pharmaceutical, medical device and biotech clients on regulatory, compliance, and distribution licensing issues related to the sales, marketing and reimbursement of marketed products.
Spanning a 25-year career in the life sciences industry, Ed Crowe, Director, Porzio Life Sciences, LLC, has held senior positions in leading companies, including Pfizer, AstraZeneca (through advertising firm, Saatchi & Saatchi), Johnson & Johnson, Abbott Laboratories, and Biomet. He led and managed teams in the areas of sales, marketing, sales training, medical education, R&D portfolio planning/execution, thought leader and medical society interactions, licensing/acquisitions, study group management and compliance.
Topic: Rock the Rules: Medical Device Marketing and the New Realities: Rock the Rules is an event within an event. KHJ, a Boston-based brand activation firm, will turn the tables on the unwritten laws of medical device marketing. Expect to be challenged and inspired as brand experts with deep experience in med device lay out four rules guaranteed to turn up the volume on your marketing efforts. Take notes and take note: these are not the Ries and Trout rules you thought you knew—they’re a new take for the new world we’re in. Don’t miss it.
Judy Habib, President/CEO KHJ Brand Activation: Since co-founding KHJ Brand Activation with Greg John in 1986, Judy Habib has continuously evolved the firm’s unique ability to serve up brilliant strategic positioning and actionable, revenue-enhancing sales support. Judy serves on the board of directors of St. Jude Children’s Research Hospital.
Rob Kinslow, Sr. Strategist, KHJ Brand Activation, helps clients forge competitive brand strategies and drive them forward through all channels and communications. He has specialized for most of his career in health-related markets, including hospital, medical device, diagnostics, life science research and drug discovery and development.